Tissue specificity is one of the central ideas in peptide-bioregulation research associated with Vladimir Khavinson and his collaborators. Broadly, it describes the observation that certain short peptides can produce different biological responses depending on the cell or tissue type. It is important, however, to distinguish experimentally observed selectivity from the stronger claim that a peptide acts exclusively on one organ.
This article expands on our main page about peptide bioregulation by examining the experiments behind the concept, later findings concerning gene expression and the limitations of the available evidence.
Where did the idea of tissue specificity come from?
Early peptide-bioregulation research isolated low-molecular-weight peptide fractions from different animal organs and tissues. Very short peptides associated with these complexes were subsequently synthesised and investigated to determine whether they showed different activity in particular tissues.
A key experiment was published in 2001 in the Bulletin of Experimental Biology and Medicine. Cortagen, Epithalon, Livagen and Vilon were studied in organotypic rat cultures. The authors reported growth stimulation respectively in explants of cerebral cortex, subcortical structures, liver and thymus – tissues corresponding to the peptide complexes associated with the development of these synthetic peptides.
This is an important experimental observation because it demonstrates selectivity within a defined model. It is, however, a preclinical organotypic rat-tissue experiment, not evidence that the same degree of organ selectivity occurs when a peptide is administered to a human.
What is an organotypic culture?
Organotypic culture uses small tissue fragments, or explants, maintained outside the organism. Unlike a culture containing only one isolated cell type, an explant preserves some of the relationships between different cellular populations within the tissue.
Researchers can therefore compare whether a substance stimulates or inhibits cellular growth and migration around the explant.
The model is useful for studying biological activity, but it has an important limitation: it does not fully reproduce metabolism, circulation, substance distribution or interactions between organs in a living organism.
From tissue growth to cellular differentiation
Later studies from the same research school shifted attention from explant growth towards molecular markers.
A 2012 publication studied human embryonic pancreatic and bronchial cell cultures and human prostatic fibroblasts. The authors reported that Pancragen (Lys-Glu-Asp-Trp), Bronchogen (Ala-Glu-Asp-Leu) and Vesugen (Lys-Glu-Asp) affected different factors associated with cellular differentiation in a tissue-dependent manner.
In the same study, the effects were more pronounced in late-passage cultures used as a model of cellular ageing. This supports the hypothesis that responses to particular short peptides may depend not only on tissue type but also on the functional state of the cells.
What is the connection with gene expression?
Another important line of research concerns the possible influence of short peptides on gene expression.
Publications by Khavinson and colleagues propose a mechanism in which some short peptides may enter cells and cell nuclei and interact with DNA or other components of chromatin.
A 2016 study modelled complexes between 19 short peptides and DNA and proposed preferred sequences for interaction. The authors considered the possibility that such interactions participate in the regulation of gene expression.
An important qualification is necessary here: the authors themselves state that a single short peptide may influence the expression of multiple genes and that the molecular mechanism remains incompletely understood.
The simple model “particular peptide → particular DNA sequence → activation of a specific gene” should therefore be regarded as a mechanistic hypothesis supported by certain experimental findings, rather than as a universally established explanation of peptide bioregulation.
What do more recent studies add?
A 2021 systematic review examined evidence concerning interactions of short peptides with DNA, histones and nucleosomes, as well as changes in gene expression and DNA methylation.
This broadens the original concept. If short peptides participate in regulation of gene activity, the mechanism may be more complex than direct interaction with a single DNA sequence and may involve several components of chromatin.
The review is useful for tracing the development of this scientific hypothesis, but it has an important limitation: a substantial part of the research discussed in it, as well as the review itself, originates from Khavinson and researchers associated with the same scientific school.
Published findings should therefore not automatically be equated with broad independent confirmation of the entire proposed mechanism.
What does “tissue-specific” mean?
Based on the available experimental evidence, the most cautious interpretation is a different or preferential biological effect within a particular experimental tissue context.
Tissue specificity does not automatically demonstrate that:
- the peptide reaches only one particular organ;
- the peptide has no effects in other tissues;
- selectivity observed in vitro is preserved to the same degree in vivo;
- a change in a molecular marker produces a clinically meaningful benefit;
- a change in gene expression automatically means prevention or treatment of disease;
- a finished dietary or other commercial product is equivalent to the particular peptide, dose and experimental conditions used in a study.
Three different levels of evidence
To interpret the literature correctly, it is useful to distinguish three levels.
1. Experimental observation
Certain peptides produce different effects in particular cellular or organotypic models. This is an observation that can be measured and independently tested.
2. Proposed mechanism
Some of these effects may involve regulation of gene expression and interactions with DNA, histones or other components of chromatin. The precise mechanism cannot yet be regarded as definitively established.
3. Clinical application
Clinical effectiveness must be demonstrated separately in humans for a particular peptide or peptide complex, dose, route of administration and clinical outcome.
The transition from an experimental observation to clinical effectiveness cannot be assumed automatically.
Why does the subject remain scientifically interesting?
The principal value of the tissue-specificity concept is that it poses a testable scientific question: can very short peptide sequences participate in context-dependent regulation of cellular function and gene expression?
Early organotypic experiments and subsequent cellular and molecular studies provide reasons to investigate this question further.
For more convincing confirmation according to modern scientific standards, particularly important areas include:
- independent replication by different research groups;
- better-characterised pharmacokinetics;
- investigation of the distribution of individual peptides within the organism;
- demonstration of their exposure to relevant cells and cellular structures in vivo;
- further clarification of molecular mechanisms;
- high-quality controlled clinical trials for specific applications.
Frequently asked questions
Does tissue specificity mean that each peptide bioregulator acts only on one organ?
No. The studies demonstrate selective effects in defined experimental models. They do not establish absolute organ specificity in the human body.
Is there experimental evidence for tissue specificity?
Yes. Published organotypic and cellular studies include the 2001 experiment with Cortagen, Epithalon, Livagen and Vilon and the 2012 study of factors associated with cellular differentiation. These findings are predominantly preclinical.
Has direct interaction between short peptides and DNA been demonstrated?
Experimental findings and molecular models of interactions between certain short peptides and DNA have been published. This does not establish a single universal mechanism through which all peptide bioregulators regulate genes in the human body.
Does a change in gene expression demonstrate clinical effectiveness?
No. A change in gene expression or another cellular marker is a biological observation. Clinical benefit must be demonstrated separately through appropriate human studies.
Do these experiments prove that a particular product treats disease in the corresponding organ?
No. Tissue specificity in an experimental model does not demonstrate the clinical effectiveness of a particular commercial product.
Scientific sources
- Khavinson VK. Tissue-Specific Effects of Peptides. Bulletin of Experimental Biology and Medicine. 2001;132(2):807–808. PMID: 11713572. DOI: 10.1023/A:1013058701974.
- Khavinson VK, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine. 2012;153(1):148–151. PMID: 22808515. DOI: 10.1007/s10517-012-1664-1.
- Khavinson VK, Linkova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bulletin of Experimental Biology and Medicine. 2016;162(2):288–292. PMID: 27909961. DOI: 10.1007/s10517-016-3596-7.
- Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. DOI: 10.3390/molecules26227053.
Important: This article is intended for informational and educational purposes. It is not medical advice and does not demonstrate that any particular peptide or product prevents, diagnoses or treats disease.
